Trials / Withdrawn
WithdrawnNCT03220399
Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2
Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2 in Healthy Male Volunteers
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- NVP Healthcare · Industry
- Sex
- Male
- Age
- 19 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to compare the pharmacokinetics and safety/tolerability between NVP-1603-1 and NVP-1603-2
Detailed description
pharmacokinetics and safety/tolerability between NVP-1603-1 and NVP-1603-2
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NVP-1603-1 (P) | 1capsule, single oral dosing |
| DRUG | NVP-1603-2 (T) | 1tablet, single oral dosing |
| DRUG | NVP-1603-1 and NVP-1603-2 (P+T) | 1capsule and 1tablet co-administration, oral single dosing |
Timeline
- Start date
- 2019-12-01
- Primary completion
- 2020-03-28
- Completion
- 2020-07-31
- First posted
- 2017-07-18
- Last updated
- 2019-08-26
Source: ClinicalTrials.gov record NCT03220399. Inclusion in this directory is not an endorsement.